Irinotecan toxicity to human blood cells in vitro: Relationship between various biomarkers

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 6, 2007, Pages 403-413

  Kopjar, Nevenka ^a   Želježić, Davor ^a   Vrdoljak, Ana Lucić ^a   Radić, Božica ^a   Ramić, Snježana ^a   Milić, Mirta ^a   Gamulin, Marija ^b   Pavlica, Vesna ^c   Fučić, Aleksandra ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b KBC Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BIOLOGICAL MARKER; IRINOTECAN;

ADULT; ANALYTIC METHOD; APOPTOSIS; ARTICLE; BLOOD CELL; BLOOD TOXICITY; CHROMOSOME 1; CHROMOSOME 2; CHROMOSOME 4; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LYMPHOCYTE; NECROSIS; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SISTER CHROMATID; STRUCTURAL CHROMOSOME ABERRATION;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL MARKERS; CAMPTOTHECIN; CHOLINESTERASE INHIBITORS; CHROMOSOMES, HUMAN, 1-3; CHROMOSOMES, HUMAN, 4-5; COMET ASSAY; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HUMANS; LYMPHOCYTES; SISTER CHROMATID EXCHANGE;

EID: 34248655415     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00068.x     Document Type: Article

References (60)

1. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumour resistance and novel strategies for modulating its activity. Ann Oncol 2002 13 : 841 51.
2. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998 1400 : 107 19.
3. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998 34 : 1500 8.
4. Wilkinson K. Irinotecan hydrochloride. Clin J Oncol Nurs 2001 5 : 179 81.
5. Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998 12 : 72 8.
6. McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 2004 22 : 1356 9.
7. Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 2003 3 : 225 37.
8. Aiuti F, Cerottini JC, Coombs RRA et al. Identification, enumeration and isolation of B and T lymphocytes from human peripheral blood. Report of a WHO/IARC-Sponsored Workshop on Human B and T Cells, London, 15-17 July 1974. Scand J Immunol 1974 3 : 521 32.
9. Duke RC, Cohen JJ. Morphological and biochemical assays of apoptosis. In : Coligan JE, Kruisbeal AM (eds) Current Protocols in Immunology. John Willey and Sons, New York, 1992 1 3.
10. Singh NP, McCoy MT, Tice RR, Schneider LL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988 175 : 184 91.
11. Wojewódzka M, Gradzka I, Buraczewska I. Modified neutral comet assay for human lymphocytes. Nukleonika 2002 47 : 1 5.
12. Albertini RJ, Anderson D, Douglas GR et al. ICPS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res 2000 463 : 111 72.
13. International Atomic Energy Agency (IAEA). Cytogenetic Analysis for Radiation Dose Assessment: A Manual, Technical Reports Series No. 405. IAEA, Vienna, Austria, 2001.
14. Tucker JD, Morgan WF, Awa AA et al. A proposed system for scoring structural aberrations detected by chromosome painting. Cytogenet Cell Genet 1995 68 : 211 21.
15. Latt S, Allen J, Bloom SE et al. Sister chromatid exchanges: a report of the gene-tox program. Mutat Res 1981 87 : 17 62.
16. Perry P, Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature 1974 261 : 156 8.
17. Lamberti L, Bigatti Ponzetto P, Ardito G. Cell kinetics and sister-chromatid exchange frequency in human lymphocytes. Mutat Res 1983 120 : 193 9.
18. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985 147 : 29 36.
19. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003 534 : 65 75.
20. Eastmond DA, Tucker JD. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and antikinetochore antibody. Environ Mol Mutagen 1989 13 : 34 43.
21. Ellman GL, Courtney KD, Andres VJ, Featherstone RM. A new and rapid colorimetric detremination of acetylcholinesterase activity. Biochem Pharmacol 1961 7 : 88 95.
22. Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalysed to SN-38 by butyrylcholinesterase. Cancer Res 1999 59 : 1458 63.
23. Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 1999 56 : 1346 53.
24. Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002 520 : 47 56.
25. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000 922 : 1 10.
26. Pizzolato JF, Saltz L. The camptothecins. Lancet 2003 361 : 2235 42.
27. Pfeiffer P, Goedecke W, Obe G. Mechanisms of DNA double strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 2001 15 : 289 302.
28. Tice RR. The single cell gel/comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. In : Phillips DH, Vennit S (eds) Environmental Mutagenesis. Bios Scientific Publishers Ltd., Oxford, UK, 1995 315 39.
29. Sané AT, Cantin AM, Paquette B, Wagner JR. Ascorbate modulation of H2O2 and camptothecin-induced cell death in Jurkat cells. Cancer Chemother Pharmacol 2004 54 : 315 21.
30. Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukaemia HL-60 cells. Jpn J Cancer Res 1993 84 : 566 73.
31. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998 1400 : 195 211.
32. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: evidence for cell cycle independent toxicity. J Cell Biol 1996 134 : 757 70.
33. Mosesso P, Fonti E, Bassi L, Lorenti Garcia C, Palitti F. The involvement of chromatin condensation in camptothecin-induced chromosome breaks in G0 human lymphocytes. Mutagenesis 1999 14 : 103 5.
34. Morton NE. Parameters of the human genome. PNAS 1991 88 : 7474 76.
35. Hoffmann GR, Sayer AM, Joiner EE, McFee AF, Littlefield LG. Analysis by FISH of the spectrum of chromosome aberrations induced by X-rays in G0 human lymphocytes and their fate through mitotic divisions in culture. Environ Mol Mutagen 1999 33 : 94 110.
36. Boei JJ, Vermeulen S, Fomina J, Natarajan AT. Detection of incomplete exchanges and interstitial fragments in X-irradiated human lymphocytes using a telomeric PNA probe. Int J Radiat Biol 1998 73 : 599 603.
37. Deng W, Lucas JN. Combined FISH with pan-telomeric PNA and whole chromosome-specific DNA probes to detect complete and incomplete chromosomal exchanges in human lymphocytes. Int J Radiat Biol 1999 75 : 1107 12.
38. Ganguly BB, Romm H, Pressl S, Stephan G. Involvement of specific chromosomes in radiation-induced rearrangements detected by fluorescence in situ hybridization (FISH). J Environ Pathol Toxicol Oncol 2000 19 : 319 23.
39. Braselmann H, Kulka U, Huber R, Figel HM, Zitzelsberger H. Distribution of radiation-induced exchange aberrations in all human chromosomes. Int J Radiat Biol 2003 79 : 393 403.
40. Anderson RM, Sumption ND, Papworth DG, Goodhead DT. Chromosome breakpoint distribution of damage induced in peripheral blood lymphocytes by densely ionizing radiation. Int J Radiat Biol 2006 82 : 49 58.
41. Boei JJ, Vermeulen S, Natarajan AT. Differential involvement of chromosomes 1 and 4 in the formation of chromosomal aberrations in human lymphocytes after X-irradiation. Int J Radiat Biol 1997 72 : 139 45.
42. Puerto S, Surralles J, Ramirez MJ, Carbonell E, Creus A, Marcos R. Analysis of bleomycin- and cytosine arabinoside-induced chromosome aberrations involving chromosomes 1 and 4 by painting FISH. Mutat Res 1999 439 : 3 11.
43. Satoh T, Hatanaka M, Yamamoto K, Kuro M, Sofuni T. Application of mFISH for the analysis of chemically induced chromosomal aberrations: a model for the formation of triradial chromosomes. Mutat Res 2002 504 : 57 65.
44. Kojima A, Shinkai T, Saijo N. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn J Clin Oncol 1993 23 : 116 22.
45. Karaberis E, Mourelatos D. Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics. Teratogen Carcinogen Mutagen 2000 20 : 141 6.
46. Bruno S, Giaretti W, Darzynkiewicz Z. Effect of camptothecin on mitogenic stimulation of human lymphocytes: involvement of DNA topoisomerase I in cell transition form G0 to G1 phase of the cell cycle and DNA replication. J Cell Physiol 1992 151 : 478 86.
47. Córtes F, Pastor N, Mateos S, Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 2003 543 : 59 66.
48. Nakatsu S, Kondo S, Kondo Y et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 1997 39 : 417 23.
49. Fenech M, Crott JW. Micronuclei, nucleoplasmic bridges and nuclear buds induced in folic acid deficient human lymphocytes - evidence for breakage-fusion cycles in the cytokinesis-block micronucleus assay. Mutat Res 2002 504 : 131 6.
50. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert E. Determinants of the cytotoxicity of irinotecan it two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002 49 : 329 335.
51. Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalized to SN-38 by butyrilcholinesterase. Cancer Res 1999 59 : 1458 63.
52. Shingyoji M, Takiguchi Y, Watanabe-Uruma R et al. In vitro conversion of irinotecan to SN-38 in human plasma. Cancer Sci 2004 95 : 537 40.
53. Massoulié J, Anselmet A, Bon S et al. The polymorphism of acetylcholinesterase: post-translation processing, quaternary associations and localization. Chem Biol Interact 1999 119-120 : 29 42.
54. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994 34 : 281 320.
55. Gandia D, Abigerges D, Armand JP et al. CPT-11-induced cholinergic effects in cancer patients (letter). J Clin Oncol 1993 11 : 196 7.
56. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1- piperidino]-carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994 54 : 427 36.
57. Pitot HC, Goldberg RM, Reid JM et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-3-week dosing schedule for patients with advanced solid tumour malignancy. Clin Cancer Res 2000 6 : 2236 44.
58. Taylor P. Anticholinesterase agents. In : Hardman JG, Limbird LE, Malinoff PB, Ruddon RW, Gillma AG (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill, New York, 1996 161 76.
59. Yu QS, Atack JR, Rapoport SI, Brossi A. Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FESB Lett 1988 234 : 127 30.
60. Rampa A, Bisi A, Valenti P et al. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of ω-[N-methyl-N-(3- alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxy-heteroaryl derivatives. J Med Chem 1998 41 : 3976 86.